Sign in

CIK 0001640266 · Accelerated filer<br>Smaller reporting company

Voyager Therapeutics, Inc.

Sign in to watch
Ticker
VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
857-259-5340
Business address
75 HAYDEN AVENUE, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-02-18 Carter Todd Alfred Chief Scientific Officer Sale 10b5-1 −3,301 $3.44 $11K 149,892
2026-02-18 Sandrock Alfred President and CEO Sale 10b5-1 −11,732 $3.41 $40K 498,257
2026-02-10 Swartz Robin COO & CBO Sale −4,569 $3.85 $18K 210,078
2026-02-10 Sandrock Alfred President and CEO Sale −12,192 $3.78 $46K 509,989
2026-02-10 Carter Todd Alfred Chief Scientific Officer Sale −3,525 $3.85 $14K 153,193
2026-02-06 Ferguson Toby Chief Medical Officer Grant or award +45,000 183,914
2026-02-06 Ferguson Toby Chief Medical Officer Grant or award · Stock Option (Right to Buy) +210,000 210,000
2026-02-06 Carter Todd Alfred Chief Scientific Officer Grant or award +33,000 156,718
2026-02-06 Carter Todd Alfred Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +154,000 154,000
2026-02-06 Swartz Robin COO & CBO Grant or award +45,000 214,647
2026-02-06 Swartz Robin COO & CBO Grant or award · Stock Option (Right to Buy) +210,000 210,000
2026-02-06 Sandrock Alfred President and CEO Grant or award +86,250 522,181
2026-02-06 Sandrock Alfred President and CEO Grant or award · Stock Option (Right to Buy) +402,500 402,500
2026-02-06 Jorgensen Nathan D. Chief Financial Officer Grant or award +32,250 156,084
2026-02-06 Jorgensen Nathan D. Chief Financial Officer Grant or award · Stock Option (Right to Buy) +150,500 150,500
2026-01-06 Shiferman Gregory L. SVP and General Counsel Grant or award · Stock Option (Right to Buy) +100,000 100,000
2025-10-03 Jorgensen Nathan D. Chief Financial Officer Sale 10b5-1 −7,666 $4.78 $37K 123,834
2025-08-18 Ferguson Toby Chief Medical Officer Sale −19,000 $3.73 $71K 138,914
2025-06-03 Vitale Nancy Director Grant or award · Stock Option (Right to Buy) +24,000 24,000
2025-06-03 SCANGOS GEORGE A Director Grant or award · Stock Option (Right to Buy) +24,000 24,000

Page 2 of 7 · 130 trades